Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Perspective Therapeutics Inc CATX

Healthcare Biotechnology
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:CATX)

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

GlobeNewswire 4 days ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

GlobeNewswire 10 days ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

GlobeNewswire 13 days ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

GlobeNewswire October 31, 2024

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

GlobeNewswire October 29, 2024

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswire October 23, 2024

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

GlobeNewswire October 16, 2024

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

GlobeNewswire October 11, 2024

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

GlobeNewswire October 10, 2024
View More News ››

Opinion & Analysis (NYSEAM:CATX)

U.S. Biotech Rolls Out New Brachytherapy Delivery Tool Used for Prostate Cancer

Streetwise Reports October 1, 2019

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters

Streetwise Reports October 4, 2018

Coverage Initiated on Developer of Brachytherapy Products for Cancer Treatment

Streetwise Reports August 22, 2018

Medical device firm boosts quarterly revenue 50% YOY

Streetwise Reports January 31, 2018
View More Opinion ››

Bullboard Posts (NYSEAM:CATX)

Perspective Therapeutics to Pursue Dose Escalation of [212Pb

BREAKING NEWS: $CATX Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-?-NET in its Ongoing Phase 1/2a Clinical Trial...
whytestocks - 4 days ago

CATX.....Yowser....huge volume increase to move it

to H.O.D Ya just never know Dang 2x's Dang !!!!!
Iseneschal - September 18, 2023

CATX....dang !!!!!!

It popped
Iseneschal - September 18, 2023

CATX....no chasing for me

No position
Iseneschal - September 18, 2023

CATX.....running and on Watch list

42 pesos
Iseneschal - September 18, 2023

world need this!

considering the options of orafice's, a winner!
north40 - January 16, 2021
View more Bullboard ››

Vista Gold Corp.

Vista Gold Corp.

Vista Gold Corp. (NYSE American and TSX: VGZ) holds the Mt Todd gold project, a shovel-ready development-stage deposit ...
View More »